$5.00
| Author | Andrew J. Krentz, Christian Weyer, Marcus Hompesch |
|---|---|
| Edition | 2 |
| Edition Year | 2019 |
| Format | |
| ISBN | 9783030117481 |
| Language | English |
| Number Of Pages | 557 |
| Publisher | Springer International Publishing |
This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders.
| Author | Andrew J. Krentz, Christian Weyer, Marcus Hompesch |
|---|---|
| Edition | 2 |
| Edition Year | 2019 |
| Format | |
| ISBN | 9783030117481 |
| Language | English |
| Number Of Pages | 557 |
| Publisher | Springer International Publishing |
Reviews
There are no reviews yet.